Glenmark Pharma’s US arm will launch Eribulin Mesylate Injection, a complex generic for breast cancer treatment, in September 2025.
Glenmark Pharma’s US arm will launch Eribulin Mesylate Injection, a complex generic for breast cancer treatment, in September 2025.